The Technical Analyst
vTv Therapeutics Inc [VTVT]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
vTv Therapeutics Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
2.18% $26.97
America/New_York / 26 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 65.60 mill |
| EPS: | -9.71 |
| P/E: | -2.78 |
| Earnings Date: | May 09, 2024 |
| SharesOutstanding: | 2.43 mill |
| Avg Daily Volume: | 0.0692 mill |
| RATING 2024-04-25 |
|---|
| B- |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Strong Sell | |
| DE: | Strong Sell | |
| P/E: | Neutral | |
| Price To Book: | Strong Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | |||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -2.78 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.47x |
| Company: PE -2.78 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$4.28 (-84.14%) $-22.69 |
| Date: 2024-04-26 |
| Expected Trading Range (DAY) |
|---|
|
$ 24.43 - 29.51 ( +/- 9.40%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-03-13 | Phillips Anne M. | Buy | 0 | |
| 2024-03-05 | Baker Bros. Advisors Lp | Buy | 52 925 | Prefunded Warrants |
| 2024-03-05 | Baker Bros. Advisors Lp | Buy | 4 780 | Prefunded Warrants |
| 2024-03-05 | Baker Bros. Advisors Lp | Sell | 52 881 | Common Stock |
| 2024-03-05 | Baker Bros. Advisors Lp | Sell | 4 776 | Common Stock |
| INSIDER POWER |
|---|
| 59.71 |
| Last 83 transactions |
| Buy: 13 416 272 | Sell: 2 785 487 |
Forecast:
16:00 - $26.97
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $26.97
Forecast 2: 16:00 - $26.97
Forecast 3: 16:00 - $26.97
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 |
| Volume Signals | |
|---|---|
| Price | $26.97 (2.18% ) |
| Volume | 0.0023 mill |
| Avg. Vol. | 0.0692 mill |
| % of Avg. Vol | 3.30 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For VTVT
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
VTVT
vTv Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on the development of orally administered treatments for diabetes. The company is developing TTP399, an orally administered, small molecule, and liver-selective glucokinase activator for the treatment of type 1 diabetes; and HPP737, an orally administered non-CNS penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases and psoriasis. It is also involved in the clinical development of other programs, including TTP273, an oral small molecule GLP-1 receptor agonist for postprandial glucose excursion to treat cystic fibrosis related diabetes; HPP3033, a non-electrophilic therapeutic approach to activating the Nrf2 pathway for the treatment of chronic diseases associated with oxidative stress; azeliragon, a RAGE antagonist for inflammatory lung diseases, including severe COVID-19, as well as for pancreatic and breast cancers; and HPP971, an Nrf2 activator for renal diseases through partnerships with pharmaceutical partners. The company has a license agreement with Reneo Pharmaceuticals, Inc. to develop and commercialize peroxisome proliferation activated receptor delta agonist program, including the compound HPP593. vTv Therapeutics Inc. also has license and research agreements with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.; Newsoara Biopharma Co., Ltd.; JDRF International; and Novo Nordisk A/S. The company was incorporated in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of MacAndrews & Forbes Incorporated.
Latest Press Releases
2024-03-19 08:30:00 - Press Release
Cantex Pharmaceuticals To Present At 5th Annual Glioblastoma Drug Development Summit
Podium presentation will include clinical updates from the company's phase 2 clinical trials investigating azeliragon, in combination with radiation therapy with or without temozolomide, in newly diagnosed glioblastoma weston, fla., march 19, 2024 /prnewswire/ -- cantex pharmaceuticals, inc., a clinical stage pharmaceutical company focused on developing transformative therapies for cancer and other life-threatening medical conditions for which new treatments are urgently needed, announced today that the company's ceo, stephen marcus, m.d.
2024-03-13 08:00:00 - Press Release
Vtv Therapeutics Announces 2023 Fourth Quarter And Full Year Financial Results And Provides Corporate Update
High point, n.c., march 13, 2024 (globe newswire) -- vtv therapeutics inc. (nasdaq: vtvt), a clinical stage biopharmaceutical company focused on the development of an oral adjunctive therapy to insulin for the treatment of type 1 diabetes (t1d), today reported financial results for the fourth quarter and year ended december 31, 2023, and provided an update on recent corporate developments.
2024-03-04 08:00:00 - Press Release
Vtv Therapeutics Announces Fda Submission For First Phase 3 Study Of Cadisegliatin In Patients With Type 1 Diabetes
High point, n.c., march 04, 2024 (globe newswire) -- vtv therapeutics inc. (nasdaq: vtvt), a clinical stage biopharmaceutical company focused on the development of cadisegliatin (ttp399) as an adjunctive therapy to insulin for the treatment of type 1 diabetes ("t1d"), today announced the submission of the study protocol to the fda for the company's first phase 3 trial evaluating the safety and efficacy of its lead candidate, cadisegliatin, in adults diagnosed with t1d.
2024-03-01 08:00:00 - Press Release
Vtv Therapeutics To Participate At The Td Cowen 44th Annual Healthcare Conference
High point, n.c., march 01, 2024 (globe newswire) -- vtv therapeutics inc. (nasdaq: vtvt), a clinical stage biopharmaceutical company focused on the development of cadisegliatin (ttp399) as an adjunctive therapy to insulin for the treatment of type 1 diabetes ("t1d"), today announced that company management will be presenting at the td cowen 44th annual healthcare conference, being held march 4-6, 2024, in boston, ma. the presentation is scheduled for tuesday, march 5, 2024, at 9:50 am et.
2024-02-28 08:00:00 - Press Release
Vtv Therapeutics Announces $51 Million Private Placement From Healthcare-focused Institutional Investors And The Jdrf T1d Fund
Proceeds to fully fund first phase 3 study of cadisegliatin, expected to initiate in mid-2024 proceeds to fully fund first phase 3 study of cadisegliatin, expected to initiate in mid-2024
Latest News
2024-03-04 15:49:34 - InvestorPlace
The Top 3 Healthcare Stocks to Buy on Weakness in 2024
Healthcare stocks have started the year off very strongly, propelled by excitement about weight loss drugs and investments by Nvidia (NASDAQ: NVDA ). The sector is also getting a lift from the U.S. Federal Reserve's decision to stop raising rates and its suggestions that it will cut rates later this year.
2023-09-22 05:22:36 - InvestorPlace
3 Tumbling Stocks to Take a Chance On Now
Some investors believe that the market is always correct and that stock prices always accurately reflect reality. As a result, they will rarely if ever buy stocks that are tumbling and that are out of favor with the market.
2023-06-15 07:33:00 - PRNewsWire
CANTEX PHARMACEUTICALS TO PRESENT AT THE MEDINVEST ONCOLOGY INVESTOR CONFERENCE IN BOSTON
WESTON, Fla. , June 15, 2023 /PRNewswire/ -- Cantex Pharmaceuticals, Inc., a clinical-stage pharmaceutical company focused on developing transformative therapies for cancer and other life-threatening medical conditions for which new treatments are urgently needed, today announced that it will present at the MedInvest Oncology Investor Conference being held June 21-22, 2023, in Boston, MA.
2023-06-12 11:29:52 - InvestorPlace
7 High-Risk, High-Reward Stocks to Buy in June
There are some similarities between gambling and buying high-risk, high-reward stocks. In both scenarios, you could make a great deal of money or you could lose all of it.
2023-04-18 08:17:55 - MarketBeat
Promising Upsides on these Biotech Penny Stocks
For investors willing to do their research and take calculated risks, biotech penny stocks can offer the potential for high returns. These companies have a low market capitalization and are not yet profitable, but they offer the potential for high growth as their products gain regulatory approval and market acceptance.
2023-03-09 14:31:53 - PennyStocks
10 Hot Penny Stocks Under $1 To Watch This Week
Penny stocks under $1 to watch right now. The post 10 Hot Penny Stocks Under $1 To Watch This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
2023-03-07 14:23:25 - PennyStocks
7 Hot Penny Stocks Under $1 To Watch This Week
Penny stocks under $1 to watch this week. The post 7 Hot Penny Stocks Under $1 To Watch This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
2023-03-06 12:19:03 - PennyStocks
Best Penny Stocks To Buy Under $1? 4 To Watch Now
2022-12-22 06:00:42 - InvestorPlace
7 Drug Stocks That Will Soar in 2023
Choosing the best drug stocks to buy can be dicey because drug stocks have disadvantages and advantages. On the negative side, you often have to wait many years for promising drugs to prove themselves in clinical trials.
2022-11-10 20:18:19 - Zacks Investment Research
VTv Therapeutics (VTVT) Reports Q3 Loss, Lags Revenue Estimates
vTv Therapeutics (VTVT) delivered earnings and revenue surprises of 0% and 100%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?